Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Subcutaneous Infusions of 3 Doses of a Novel Somatostatin Analogue, DG3173, on Growth Hormone Levels in Untreated Acromegalics

NCT02217800 is registered in ClinicalTrials.gov with Aspireo Pharmaceuticals Limited as lead sponsor.

NCT NCT02217800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02217800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Subcutaneous Infusions of 3 Doses of a Novel Somatostatin Analogue, DG3173, on Growth Hormone Levels in Untreated Acromegalics
Lead sponsor
Aspireo Pharmaceuticals Limited
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2013
Completion date
May 31, 2016
Enrollment
8 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acromegaly